AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Index funds and bonds serve different roles in a diversified portfolio. This guide explains when index funds may be preferred over bonds and how to balance exposure.
25,248 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Two fast-food giants shape the investing landscape with very different revenue engines. This analysis dives into how ...
A high-stakes NBA scenario puts investor attention on payroll, sponsorships, and market bets. The potential LeBron mo...
UBS researchers say infrastructure stocks have overtaken hyperscalers in AI spending, signaling a shift in AI infrast...
A high-profile ruling on copyright claims offers a blueprint for managing legal risk and protecting earnings. This ar...
Strategy disrupted the market by using Bitcoin as a cash engine. The recent $216 million sale to fund dividends promp...
A disciplined investment approach blends steady dividend payers with selective high-yield assets to produce durable i...
Robinhood accelerates its blockchain push to compete with Coinbase, while Base narrows its focus to trading, payments...
Ripple (XRP) ETFs resume inflows as fresh capital returns to the XRP ETF space, but reporting gaps leave traders wary...
Data centers are growing fast, driven by cloud and AI. The real engine? Utilities expanding power capacity and reliab...
Xenon stock sits at $42 as insiders trim significant positions ahead of a pivotal March Phase 3 readout. This guide b...
Prediction markets have spoken: a strong probability Nvidia beats earnings. Learn what these odds mean, how reliable ...